11 November, 2023

The Victorian Evolution of Inherited Retinal Diseases Natural History Registry (VENTURE) Study is a collaboration between the Centre for Eye Research Australia and the University of Melbourne led by Associate Professor Lauren Ayton and Dr Tom Edwards.

The study aims to collect retrospective and prospective data from people with inherited retinal disease (IRD) and female carriers of X-linked IRD.

The purpose of the registry is to enable:

  • recruitment for investigator-initiated research studies, including longitudinal natural history studies and genotype/phenotype studies, and
  • to identify people who may be eligible for upcoming industry-sponsored clinical trials.

What is involved in participating in the Study?

  • Participants can choose to be remotely registered only (where we complete registration and surveys over the phone, and collect retrospective information from their healthcare providers) or attend a baseline research visit.
  • At the research visit, patients will undergo a comprehensive eye examination involving vision assessments, visual fields, and retinal imaging. Vision and lifestyle questionnaires will be administered to capture opinions, emotions, and daily living of people with, or female carriers of, IRD.
  • Participants can choose to return for longitudinal visits and other research studies, with no obligation to do so at any time.
  • With their opt-in consent, participants will be registered on our database to be contacted should any relevant clinical trials become available.
  • With the participant’s consent, the study team will send a report back to the referring clinicians following VENTURE related research visits.

For further details, please email IRD@groups.unimelb.edu.au or click on the button below.

 

We can’t do what we do without you!

Other Blogs

5 Years of Luxturna

5 years of Luxturna - The first gene therapy for an IRD ERN-EYE hosted a webinar in late January 2025 to mark five years since the first gene therapy for...

Podcast: Fixing the Code for Inherited Retinal Diseases

Talking Eyes with Lien Trinh Guest speaker: Dr Tom Edwards In this Talking Retina episode, Fixing...

First treatment for geographic atrophy approved in Australia

Apellis' SYFOVRE® (pegcetacoplan) TGA Approved  Apellis Pharmaceuticals, Inc. announced today that Australia’s Therapeutic Goods Administration...